Taysha Gene Therapies (TSHA) Operating Leases (2022 - 2026)
Taysha Gene Therapies (TSHA) posted Operating Leases of $17.8 million for Q1 2026, down 2.23% sequentially from $18.2 million in Q4 2025, and up 3.94% YoY from $17.1 million in Q1 2025.
Taysha Gene Therapies (TSHA) Operating Leases (2022 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Operating Leases for 5 years, with the latest figure at $17.8 million in Q1 2026.
- Quarterly Operating Leases rose 3.94% year-over-year to $17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.8 million (up 3.94% YoY) and the FY2025 annual result came in at $18.2 million, up 4.67% from the prior year.
- Operating Leases slipped to $17.8 million in Q1 2026 per TSHA's latest filing, from $18.2 million in the prior quarter.
- Over five years, Operating Leases peaked at $20.4 million in Q4 2022 and troughed at $16.5 million in Q3 2025.
- A 5-year average of $18.3 million and a median of $18.2 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2024 and 2025: Operating Leases dropped 8.4% in 2024, then increased 4.67% in 2025.
- Over 5 years, Operating Leases stood at $20.4 million in 2022, then fell by 7.27% to $19.0 million in 2023, then retreated by 8.4% to $17.4 million in 2024, then increased by 4.67% to $18.2 million in 2025, then retreated by 2.23% to $17.8 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $17.8 million, $18.2 million, and $16.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.29 Mn |
| Mar 31, 2026 | 17.77 Mn |
| Dec 31, 2025 | 18.17 Mn |
| Sep 30, 2025 | 16.51 Mn |
| Jun 30, 2025 | 16.81 Mn |
| Mar 31, 2025 | 17.09 Mn |
| Dec 31, 2024 | 17.36 Mn |
| Sep 30, 2024 | 17.75 Mn |
| Jun 30, 2024 | 18.13 Mn |
| Mar 31, 2024 | 18.50 Mn |
| Dec 31, 2023 | 18.95 Mn |
| Sep 30, 2023 | 19.10 Mn |
| Jun 30, 2023 | 19.53 Mn |
| Mar 31, 2023 | 19.93 Mn |
| Dec 31, 2022 | 20.44 Mn |